An increased risk of urinary tract infection precedes development of primary biliary cirrhosis

BMC Gastroenterology

Timothy R Card¹  Joe West²  Fumi K Varyani³ 

[1] Department of Gastroenterology, King's Mill Hospital, Mansfield Road, Sutton-In-Ashfield, NG17 4JL, UK;Nottingham Digestive Diseases Centre Biomedical Research Unit, University of Nottingham, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, UK;Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building Phase 2, Hucknall Road, Nottingham, NG5 1PB, UK

关键词: Antimitochondrial;    AMA;    Aetiology;    UTI;    PBC;   

Others  :  1113269
DOI  :  10.1186/1471-230X-11-95

 received in 2011-02-11, accepted in 2011-08-26,  发布年份 2011

【 摘 要 】

Background

Primary Biliary Cirrhosis is known to be associated with Urinary Tract Infections (UTIs), but whether these precede or follow the liver disease is unclear. We have therefore attempted to determine whether UTIs are more common in people with Primary Biliary Cirrhosis (PBC) prior to their diagnosis.

Methods

We conducted a case control study in the General Practice Research Database. All cases of PBC first recorded at least one year after entry to the dataset were selected along with up to 10 controls matched for age, sex. A second unmatched control group who had Chronic Liver Diseases but not PBC were chosen. The main exposures studied were the occurrence of Urinary tract infections and pyelonephritis at least one or at least five years before diagnosis. We also performed an analysis restricted to those younger than 55 at diagnosis, as we hypothesized the relationship to be stronger in the younger age group.

Results

PBC is associated with UTI prior to diagnosis, OR 1.50 (CI 1.26-1.78), which was similar 5 years prior to diagnosis and after adjusting for smoking. The strongest relationships were observed in pyelonephritis exposures five years before diagnosis in cases under 55 years: adjusted odds ratios were 2.60 (1.02-6.63) in comparison with matched general population controls and adjusted odds ratios were OR 2.45 (1.02-5.59) in the comparison with chronic liver disease controls.

Conclusions

We found that the association between urosepsis and PBC is specific to this disease and precedes the diagnosis of PBC in a manner not previously observed in human data. This is consistent with a causal relationship.

【 授权许可】

   
2011 Varyani et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]van de Meeberg PC, Wolfhagen FH, van Erpecum KJ, van Berge Henegouwen GP: Cholestatic liver diseases: new strategies for prevention and treatment of hepatobiliary and cholestatic diseases. Neth J Med 1995, 47(1):30-35.
• [2]Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD, et al.: Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009, 360(24):2544-2555.
• [3]Triger DR: Primary biliary cirrhosis: an epidemiological study. Br Med J 1980, 281(6243):772-775.
• [4]Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, Bach N: Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006, 43(3):525-531.
• [5]McNally RJ, Ducker S, James OF: Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology 2009, 50(4):1169-1174.
• [6]Bogdanos DP, Vergani D: Bacteria and primary biliary cirrhosis. Clin Rev Allergy Immunol 2009, 36(1):30-39.
• [7]Berg CP, Kannan TR, Klein R, Gregor M, Baseman JB, Wesselborg S, Lauber K, Stein GM: Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. Liver Int 2009, 29(6):797-809.
• [8]Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, et al.: Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38(5):1250-1257.
• [9]Smyk D, Rigopoulou EI, Baum H, Burroughs AK, Vergani D, Bogdanos DP: Autoimmunity and Environment: Am I at risk? Clin Rev Allergy Immunol 2011.
• [10]Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, Burroughs AK, Vergani D: Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis 2003, 35(11):801-805.
• [11]Bogdanos DP, Baum H, Vergani D, Burroughs AK: The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Dis Markers 2010, 29(6):301-311.
• [12]Winstanley TG, Limb DI, Eggington R, Hancock F: A 10 year survey of the antimicrobial susceptibility of urinary tract isolates in the UK: the Microbe Base project. J Antimicrob Chemother 1997, 40(4):591-594.
• [13]Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, Rigopoulou E, Montalto P, Davies ET, Burroughs AK, et al.: Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. Journal of hepatology 2004, 40(1):31-39.
• [14]Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S: Bacteriuria and primary biliary cirrhosis. Gut 1984, 25(2):133-137.
• [15]Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM: Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42(5):1194-1202.
• [16]Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF: An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology 2000, 31(5):1055-1060.
• [17]Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME: Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology 2001, 33(1):16-21.
• [18]Prince MI, Ducker SJ, James OF: Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 59(4):508-512.
• [19]Walley T, Mantgani A: The UK General Practice Research Database. Lancet 1997, 350(9084):1097-1099.
• [20]Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H: Validity of the general practice research database. Pharmacotherapy 2003, 23(5):686-689.
• [21]Metcalf JV, Bhopal RS, Gray J, Howel D, James OF: Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997, 26(4):830-836.
• [22]Hoepelman AI, Meiland R, Geerlings SE: Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003, 22(Suppl 2):35-43.
• [23]Prince M, Chetwynd A, Newman W, Metcalf JV, James OF: Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002, 123(4):1044-1051.
• [24]James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV: Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 1999, 30(2):390-394.
• [25]Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J: Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007, 46(4):1131-1137.
• [26]West J, Card TR, Solaymani-Dodaran M, Logan RFA, Aithal G: Incidence of Primary Biliary Cirrhosis: a UK population-based study. In British Association of the Study of the Liver Annual Meeting. Cambridge; 2004.
• [27]Ewies AA, Alfhaily F: Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick? Climacteric 2010, 13(5):405-418.
• [28]Amano K, Leung PS, Rieger R, Quan C, Wang X, Marik J, Suen YF, Kurth MJ, Nantz MH, Ansari AA, et al.: Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 2005, 174(9):5874-5883.
• [29]Stemerowicz R, Hopf U, Moller B, Wittenbrink C, Rodloff A, Reinhardt R, Freudenberg M, Galanos C: Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)-mutants of enterobacteriaceae? Lancet 1988, 2(8621):1166-1170.
• [30]Palermo JJ: W1846 Recurrent Urinary Tract Infection in Mice Results in Immune-Mediated Cholangiopathy Similar to Human Primary Biliary Cirrhosis. Gastroenterology 2008, 134(4, Supplement 1):A-837.
• [31]Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK: M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 1993, 17(3):408-414.